If you are a Healthcare Professional and you would like to log in to access this content, please click "Login".
You are now leaving the Lilly Medical Web site
Please use a minimum of three unique search wordsOur search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Taltz ® (ixekizumab)
This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information:
Taltz Summary of Product Characteristics (SmPC)
Taltz® (ixekizumab): Dosage Regimen for Psoriatic Arthritis
160 mg at week 0, then 80 mg every 4 weeks.
Regimen for Psoriatic Arthritis
recommended dose is 160 mg by subcutaneous injection (two 80 mg
injections) at Week 0, followed by 80 mg (one injection)
every 4 weeks thereafter.1
psoriatic arthritis patients with concomitant moderate to severe
plaque psoriasis, the recommended dosing regimen is the same as for
should be given to discontinuing treatment in patients who have shown
no response after 16 to 20 weeks of treatment. Some patients
with initially partial response may subsequently improve with
continued treatment beyond 20 weeks.1
in specific patient populations
elderly patients (≥ 65 years) is no dose adjustment required.
There is limited information in subjects aged ≥ 75 years.1
has not been studied in patients with renal or hepatic impairment. No
dose recommendations can be made.1
alone or in combination with methotrexate, is indicated for the
treatment of active psoriatic arthritis in adult patients who have
responded inadequately to, or who are intolerant to one or more
disease-modifying anti-rheumatic drug (DMARD) therapies.1
is intended for use under the guidance and supervision of a physician
experienced in the diagnosis and treatment of conditions for which
Ixekizumab is indicated.1
Taltz [summary of product characteristics]. Eli Lilly Nederland
B.V., The Netherlands.
= conventional disease-modifying antirheumatic drug
= human immunodeficiency virus
= nonsteroidal anti-inflammatory drug
= psoriatic arthritis
= every 2 weeks
= every 4 weeks
= tumor necrosis factor
Date of Last Review:June 05, 2019
Was this answer helpful to you?
Call or Email us
If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at firstname.lastname@example.org